News Releases
Feb 27 2006
Clinical Trial Results Show that Peregrine's First-In-Class Anti-Viral Agent Tarvacin(TM) is Safe and Well-Tolerated in HCV Patients
Feb 17 2006
Peregrine Pharmaceuticals to Present at Roth Capital Partners 18th Annual OC Conference
Feb 15 2006
Peregrine Announces Completion of Planned Patient Enrollment and Dosing in Initial Tarvacin(TM) Anti-Viral Hepatitis C Phase 1 Trial
Feb 9 2006
Peregrine Pharmaceuticals to Present at 2006 BIO CEO Conference
Jan 18 2006
Peregrine Pharmaceuticals Announces Second Defense Department Grant for Preclinical Tarvacin Prostate Cancer Studies
Jan 18 2006
Peregrine Announces Acceleration of Its Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program
Jan 11 2006
Newly Published Data Shows Potential of Peregrine's Tarvacin(TM) to Treat Primary and Metastatic Pancreatic Cancer
Dec 9 2005
Peregrine Pharmaceuticals Reports Fiscal Year 2006 Second Quarter Results
Dec 6 2005
Peregrine's Subsidiary Begins First Commercial Stage Drug Manufacturing Project
Dec 2 2005
Peregrine Pharmaceuticals to Host Second Quarter FY2006 Conference Call